← All trials
NCT04898894
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 15, 2021
- Primary completion
- Dec 31, 2022
- Completion date
- Jun 30, 2023
- First posted
- May 24, 2021
- Last posted
- Nov 22, 2021
- Enrollment
- 42
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- St. Jude Children's HospitalLead sponsor
- Karyopharm Therapeutics IncCollaborator
- AbbVieCollaborator
- St. Jude Children's HospitalOverall official - principal investigator
- Gateway for Cancer ResearchCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.